-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%
BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%
BriaCell Therapeutics Corp. (CVE:BCT – Get Rating)'s stock price fell 3.8% during trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Down 3.8 %
The firm has a market capitalization of C$168.68 million and a PE ratio of -28.19. The business's 50 day simple moving average is C$10.60 and its 200 day simple moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05.
Get BriaCell Therapeutics alerts:Insider Transactions at BriaCell Therapeutics
In other news, Director William Williams bought 27,272 shares of the stock in a transaction dated Thursday, July 14th. The stock was purchased at an average price of C$3.58 per share, for a total transaction of C$97,497.40. Following the acquisition, the director now owns 27,272 shares of the company's stock, valued at C$97,497.40.
About BriaCell Therapeutics
(Get Rating)BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
BriaCell Therapeutics Corp. (CVE:BCT – Get Rating)'s stock price fell 3.8% during trading on Friday . The company traded as low as C$10.60 and last traded at C$10.60. 3,402 shares were traded during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Treateutics Corp.(CVE:BCT-GET Rating)股价周五下跌3.8%。该公司股价最低跌至10.60加元,最新报10.60加元。午盘成交量为3,402股,较12,671股的平均成交量下降73%。该股此前收盘报11.02加元。
BriaCell Therapeutics Stock Down 3.8 %
Briacell治疗公司股价下跌3.8%
The firm has a market capitalization of C$168.68 million and a PE ratio of -28.19. The business's 50 day simple moving average is C$10.60 and its 200 day simple moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05.
该公司市值为1.6868亿加元,市盈率为-28.19倍。该业务的50日简单移动均线切入位在10.60加元,200日简单移动均线切入位在10.60加元。该公司的流动比率为129.63,速动比率为128.68,债务权益比率为0.05.
Insider Transactions at BriaCell Therapeutics
Briacell治疗公司的内幕交易
In other news, Director William Williams bought 27,272 shares of the stock in a transaction dated Thursday, July 14th. The stock was purchased at an average price of C$3.58 per share, for a total transaction of C$97,497.40. Following the acquisition, the director now owns 27,272 shares of the company's stock, valued at C$97,497.40.
另外,董事威廉·威廉姆斯在一笔日期为7月14日(星期四)的交易中购买了27,272股该公司股票。该股是以每股3.58加元的平均价格收购的,总交易金额为97,497.40加元。收购完成后,董事现在拥有27,272股该公司股票,价值97,497.40加元。
About BriaCell Therapeutics
Briacell治疗公司简介
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
BriaCell治疗公司是一家免疫肿瘤学生物技术公司,致力于开发癌症管理方法。它的主要候选者是Bria-IMT,这是一项与免疫检查点抑制剂联合治疗乳腺癌的I/IIa期临床试验。该公司还与国家癌症研究所签订了合作研发协议,开发针对晚期乳腺癌的现成个性化免疫疗法Bria-OTS,以及诊断测试BriaDx。
Further Reading
进一步阅读
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- Salesforce Stock Could Have Long Term Potential After Earnings
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- 机构买入让Marvell科技陷入低谷
- 戴尔股票因销售疲软而回落,跌入可怕的价值
- Dollar General的拉力赛有三个理由
- Salesforce股票在盈利后可能具有长期潜力
- 艾伯维公司。应该在你的股息投资组合中占有一席之地吗?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Briacell治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BriaCell治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧